News >

State of Immunotherapy Continues to Shift in NSCLC

Caroline Seymour
Published: Friday, Jul 13, 2018

Liza C. Villaruz, MD

Liza C. Villaruz, MD
The KEYNOTE-024 trial may have positioned pembrolizumab (Keytruda) as the frontline treatment for patients with PD-L1–overexpressing tumors, but there have been many other trials that have followed suit, explained Liza C. Villaruz, MD. Additionally, other studies continue to showcase combination immunotherapy’s potential in the first-line setting.

State of the Science Summit™ on Lung Cancer, Villaruz, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, addressed the immunotherapy clinical trials that have informed the treatment of patients with NSCLC and the current state of biomarkers in the field.

OncLive: What do we know about immunotherapy in NSCLC?

Villaruz: I covered some of the data in the second-line setting, which established single-agent immunotherapy as part of the standard of care. I focused on the KEYNOTE-024 data, which established pembrolizumab in the first-line setting for PD-L1–overexpressing tumors.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x